Transforming drug discovery: Novo Nordisk uses the power of AI and Azure with Microsoft Research
Developing high-quality medicine is a resource-intense endeavor that requires collaboration across Novo Nordisk. Novo Nordisk aimed to scale a pipeline of drug discovery, development, and data science capabilities with AI and machine learning. In partnership with Microsoft Research, the teams built a Novo Nordisk AI platform on Azure AI and data stacks. Novo Nordisk amplified its culture of innovation by leveraging Microsoft Azure platform's AI capabilities across many use cases. The teams recently published initial results with predictive AI models for advanced risk detection in cardiovascular diseases, including an algorithm that can predict patients' cardiovascular risk better than the best clinical standards. Read this case study for lessons learned.
How is Novo Nordisk using AI in drug discovery?
Novo Nordisk is leveraging AI and machine learning to enhance its drug discovery and development processes. By building a dedicated AI platform on Microsoft Azure, the company is able to scale its capabilities and improve collaboration among life scientists, computational biologists, and data scientists. This approach has led to the development of predictive AI models that can detect cardiovascular disease risks more effectively than traditional clinical standards.
What are the benefits of the partnership with Microsoft Research?
The partnership with Microsoft Research allows Novo Nordisk to combine its extensive domain expertise in life sciences with Microsoft's advanced AI capabilities. This collaboration has resulted in the creation of a comprehensive AI platform that supports various use cases, including regulatory affairs and trial design, enabling more efficient and innovative approaches to drug discovery.
What impact does AI have on patient care?
AI is reshaping patient care at Novo Nordisk by enabling the definition of patients' risks for developing diseases, which is essential for precision medicine. With over 100 years of data on insulin research, the integration of AI allows Novo Nordisk to provide better treatment options for conditions related to diabetes, such as obesity and cardiovascular diseases, ultimately improving patient outcomes.
Transforming drug discovery: Novo Nordisk uses the power of AI and Azure with Microsoft Research
published by Strategic Endeavor LLC
Strategic Endeavor, LLC, founded in 2013, is an emerging 8(A) and Service-Disabled Veteran Owned Small Business (SDVOSB) that specializes in providing management consulting, technology solutions, and administrative services to the Government and industry. Strategic Endeavor LLC is an approved Microsoft Cloud Provider and provides these services as an indirect seller in partnership with TD SYNNEX
SYNNEX Stellr Cloud Marketplace is a modern end-to-end solutions ecosystem that helps partners deliver more value to their customers. Strategic Endeavor LLC can leverage TD SYNNEX’s large number of state and local government and educational contracts and educational contracts-including NAPO ValuePoint and NCPA and NCPA directly on behalf of the manufacturers. Strategic Endeavor can also leverage TD SYNNEX GSA Schedule 58 and Schedule 70 to sell to the Federal government and its GSA Schedule SIN 511210 Software Publisher
Strategic Endeavor LLC provides the following Microsoft Solution
Microsoft 365
Helping customers build a modern workplace that allows them to work smarter and stay secure.
Office 365
+ migration services
Microsoft 365 + ISVs
+ managed services
Microsoft 365 + Azure Backup
+ DevTest + managed services
Azure practice
Azure migration, from defining a strategy to
migrating and optimizing
Contact: telephone 800-422-0381, Email: srhodes@seresults.com
Sign in with LinkedIn